Novo Nordisk's Summer of Reckoning: Prescription Dominance Meets Pipeline Verdict

A brutal disconnect is playing out at Novo Nordisk. The Danish pharma giant’s oral Wegovy tablet is flying off pharmacy shelves, yet its shares have plunged roughly 45% from the 52-week high to trade at around 293 Danish kroner (€38.26). That gulf between commercial success and market sentiment sets the stage for a pivotal few weeks, with pipeline data and competitive threats both looming.

Prescription data through late May tells a clear story of market control. In the week ending May 22, the oral version of Wegovy racked up 146,000 prescriptions, a 2% week-on-week gain. That tally is 2.4 times what Eli Lilly’s comparable oral product, Foundayo, managed at the same point after launch. Six weeks post-introduction, Novo Nordisk had 57,000 scripts versus Foundayo’s 16,000. The momentum is undeniable, even if the growth rate is slowing.

But investors are far more focused on what comes next. Starting June 5, Novo Nordisk will present 40 abstracts at the American Diabetes Association’s Scientific Sessions in New Orleans, headlined by the REIMAGINE-1-to-3 phase 3 results for CagriSema. This fixed-dose combination of semaglutide and the long-acting amylin analogue cagrilintide is being tested in type 2 diabetes patients. The market wants to see whether CagriSema can deliver superior blood sugar control and weight loss compared to existing monotherapies. Alongside that, phase 2 data for Zenagamtide—a novel once-weekly GLP-1/amylin agent—will be unveiled, along with updated cardiometabolic profiles for Ozempic and Wegovy.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

An R&D investor event on June 7 will give management the chance to flesh out the clinical results and map out the regulatory path for CagriSema, with an FDA decision expected in the fourth quarter of 2026. Analysts at William Blair have flagged that the stock’s reaction will hinge on whether the REIMAGINE data can restore confidence in Novo’s pipeline competitiveness. At a price-to-earnings ratio of roughly 11 and a dividend yield of 3.84%, the valuation already embeds plenty of skepticism.

Behind the scenes, Novo Nordisk is also leaning on its balance sheet. Since February, the company has bought back 17.9 million B-shares worth 4.71 billion Danish kroner as part of a 12-month programme targeting roughly €2 billion. On the pricing front, Novo is one of 16 manufacturers joining the new TrumpRx platform, agreeing to cap monthly costs for certain medicines between $149 and $350.

Yet headwinds are building. Citi strategists caution that Eli Lilly’s planned TV advertising campaign for Foundayo, set to begin in the third quarter of 2026, could start shifting market share. The oral Wegovy tablet’s early lead is impressive, but defending it will require more than just early mover advantage.

For Novo Nordisk, the next few weeks are about proving that the current prescription boom isn’t a fleeting win—and that the next generation of therapies can match the commercial firepower of the old. New Orleans will provide the first major verdict.

Ad

Novo Nordisk Stock: New Analysis - 1 June

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69465104 |